Selegiline, marketed under the brand name Emsam, is a medication primarily used in the management of major depressive disorder (MDD) and Parkinson's disease. It is classified as a selective monoamine oxidase inhibitor (MAOI), specifically inhibiting MAO-B enzymes. This action increases the levels of certain neurotransmitters in the brain, such as dopamine, which can enhance mood and motor function.
